News

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

The first half of 2025 recap for nephrology spotlights renal FDA action, ERA 2025 Congress coverage, and updates in xenotransplantation.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.

Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.

The first half of 2025 recap for gastroenterology spotlights GI FDA approvals, clinical trial data, and new guidance on bowel preparation for colonoscopy.

Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.

New research reveals significant links between alopecia areata and mental health issues, emphasizing the need for comprehensive care in affected individuals.

Veeral Sheth, MD, is joined by the director of marketing of eSight to discuss the 5th generation eSight Go, a device to enhance central vision functions in patients with a variety of eye diseases.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.

Gastrointestinal disorders, atopic conditions, and other diseases may have similar or shared pathogenetic mechanisms with AA, based on recent research.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

Positive topline results showed patients who received 2 scheduled rilparencel injections experienced significant eGFR slope decline improvement.

Ellis discusses new data showing EURneffy nasal spray delivers effective adrenaline even during allergic rhinitis, matching intramuscular injection.

Explore the latest advancements in pulmonology, including FDA approvals and breakthrough therapies for COPD, PAH, and rare respiratory diseases.

Check out insights from SDPA 2025 on eczema, alopecia, vitiligo, burnout, and JAK inhibitor workups—key tips to improve dermatology care.

The first half of 2025 recap for hepatology spotlights FDA approvals, clinical trial updates, and the 1-year anniversary of resmetirom.

These 16-week findings have been announced by Apogee Therapeutics on APG777 in patients with moderate-to-severe atopic dermatitis.

KalVista's therapy is now approved under the name Ekterly, the first oral therapy for hereditary angioedema, empowering patients with timely, on-demand treatment options.

These data point to several hidradenitis suppurativa drugs as most impactful for those with moderate-to-severe disease, based on Hidradenitis Suppurativa Clinical Response.

5 FDA updates in psychiatry from the first half of 2025, plus other pipeline developments in psychiatry for depression, schizophrenia, and OUD.

Hosts discuss the US launch of the Twiist from Sequel Med Tech and what it means for care providers and people with diabetes.

The Q2 recap for gastroenterology spotlights top coverage from DDW, expert perspective on the importance of multidisciplinary care, and other new research.

Based on 8 major questions and consisting of 9 formal recommendations, the SCAI’s guidelines aim to advise clinicians on what treatments to use when.

Q2 2025 saw new therapies approved for a number of rare disease indications, multiple of which serve as the first disease-modifying therapies in the landscape.